Sign in
OBSV Stock Price, Chart, Stats & News
ObsEva S.A.
Save
11.00M
Market cap
–
Current P/E
–
Forward P/E
OBSV chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -79.83% |
Pretax margin | -152.10% |
Net margin | -152.16% |
Effective tax rate | -0.04% |
ROA | -180.60% |
ROE | -146.39% |
D/E | 0.36x |
Interest coverage ratio | -1.70x |
OBSV valuation
P/E | – |
P/S | 0.56x |
P/B | 1.11x |
P/CF | -0.40x |
P/FCF | -0.48x |
P/OCF | -0.40x |
PEG | -0.00x |
EV multiple | -0.82x |
About
ObsEva S. A. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for conditions affecting women's reproductive health and pregnancy. A key part of their development pipeline is Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, currently in Phase III clinical trials.
Similar securities
Based on sector and market capitalization
Report issue